Drugs / Faster aspart
Faster aspart
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04698018 | Apr 2021 → Jul 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03723759 | Oct 2018 → Mar 2019 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03407599 | Jan → Jul 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT01682902 | Sep 2012 → Mar 2013 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04588259 | Oct 2020 → Jul 2022 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05262595 Comparator | Mar → Aug 2022 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisks nye hurtigtvirkende måltidsinsulin, Fiasp®, godkendt i USA novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (fast-acting insulin aspart) approved in Europe novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling novonordisk.com ↗ |
| 2012-12-19 | Novo Nordisk A/S | The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development novonordisk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faster Aspart | “BACKGROUND: Faster aspart is insulin aspart (IAsp) in a new formulation, which” PMID 28055230 ↗ Jan 2017 |
| Known as | Fast-acting Insulin Aspart | “Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes” NCT04588259 ↗ |
| Known as | Fiasp | “The 3 formulations of insulin NNC0471-0119 are given as one bolus on top of a constant insulin basal rate and compared to Faster Aspart (Fiasp®).” NCT05262595 ↗1“the reference product called faster aspart 100 U/mL (marketed as Fiasp®)” NCT03723759 ↗ |
| Route | Subcutaneous | “Administration: Subcutaneous infusion.” NCT01682902 ↗ |